 |
Michael Amolins graduated in May 2007 from Augustana College in Sioux Falls, SD, with a B.A. in Chemistry and minors in Mathematics and Music. He is now a first-year graduate student and Self Fellow working towards a Ph.D. in the Blagg lab. Currently, Michael’s project involves the synthesis and evaluation of natural product analogues as Hsp90 inhibitors. mamolins@ku.edu |
|---|---|
 |
Gary E. Brandt earned his B.S. in chemistry from Georgia State University in the fall of 2005. He joined the Blagg Laboratory in the Spring of 2007. Gary is currently working on the total synthesis of a natural product, which inhibits F1Fo ATP synthase, and is conducting SAR on Gedunin, a natural product recently found to inhibit HSP90. Gary is a Self Fellow. gebrandt@ku.edu |
 |
Geraldine Calvet received her Ph.D. from the University of Paris-Sud, France in September 2006, where she worked on the Lewis acid promoted nitroso Diels-Alder reaction using α-acetoxynitroso under the supervision of Dr. Nicolas Blanchard and Prof. Cyrille Kouklovsky. In November 2006 she joined the Blagg laboratory as a postdoctoral researcher and is currently working on the synthesis of Trienomycin A analogs. gfcalvet@yahoo.fr |
 |
James Clark graduated from Southern Utah University in Cedar City, UT where he received a B.S. in Chemistry in 2007. He is a first year graduate student and joined Dr. Blagg’s research group during the Spring of 2008. His current project involves the synthesis of small molecule inhibitors targeting the N-terminus of the molecular chaperone, Hsp90. jclarkny@ku.edu |
 |
Alison Donnelly is a second-year graduate student who earned her B.S. in Chemistry and B.A. in Spanish from Case Western Reserve University in Cleveland, OH in spring, 2006. Since joining the Blagg lab in fall, 2006, she has been working on a research project that involves the synthesis and evaluation of novel C-terminal Hsp90 inhibitors based on the novobiocin scaffold. adonnelly@ku.edu |
 |
Adam Duerfeldt received his Bachelors degree in chemistry from Central College in Pella, Iowa and subsequently joined the Blagg laboratory as a graduate student. Currently, Adam is working on the synthesis of chimeric molecules of geldanamycin and radicicol as N-terminal inhibitors of Hsp90. Adam is a Self fellow. aduerf@ku.edu |
 |
Kyle Hadden received his Ph.D. from the Medical University of South Carolina in 2004 where he worked on the synthesis and evaluation of centrally active peptides. After completion of postdoctoral training at the University of Wisconsin in the Department of Biochemistry, Kyle joined the Blagg laboratory in August of 2005. His current project includes the development of Hsp90 assays for high-throughput screening, optimization of small molecule HTS leads as Hsp90 inhibitors, and the synthesis of chimeric analogues of geldanamycin and radicicol. Kyle is a NIH/KUMC postdoctoral fellow. haddenmk@ku.edu |
 |
Daniela Hendea received her Ph.D. from the University of Stuttgart, Germany where she worked on diastereoselective alkylation of proline-derived lactimethers as a pathaway to biologically relevant diketopiperazines, under the supervision of Prof. Dr. Sabine Laschat. In October 2007, she joined the Blagg laboratory as a postdoctoral researcher and her current project involves the design, synthesis, biological evaluation, and molecular modelling of Hsp90 C-terminal inhibitors based on the novobiocin scaffold. dhendea@ku.edu |
 |
Stephanie Hill is currently a sophomore at The University of Kansas majoring in Chemistry and Biochemistry. She is a K-INBRE Scholarship recipient as well as a nominee for a Goldwater Scholarship. Stephanie is working on the synthesis of small molecule inhibitors of Hsp90. steph09@ku.edu |
 |
Vinod Jadhav received his Ph.D. from the Technical University of Munich, Germany in December 2005, where he worked on molecular recognition based on Guanidinium receptors under the supervision of Prof. Dr. Franz P. Schmidtchen. In January 2008, he joined the Blagg laboratory as a postdoctoral researcher and is currently working on the synthesis of geldanamycin analogs as N-terminal inhibitors of Hsp90. vinodjadhav1977@gmail.com |
 |
Yuanming Lu received his Ph.D. from the University of Fudan in China in 2001, where he worked on molecular pharmacology and toxicology. After the completion of postdoctoral training at the University of Tokushima in the Department of Molecular biology and Biochemistry in Japan, he joined the Blagg laboratory in July of 2007. His current project includes the development of Hsp90 assays for high-throughput screening and characterization of small molecule HTS leads as Hsp90 inhibitors. lu650920@ku.edu |
 |
Donna J. Lubbers Donna J. Lubbers received her B.S. degree from Saint Mary’s College at Notre Dame in May 2005. Donna joined the Blagg Lab group in January 2006 and is currently in her third year of the Ph.D. program. Her projects include synthesis and SAR studies as well as molecular modeling and docking studies of C-terminal Hsp90 inhibitors. Donna is a Self fellow. donnaj@ku.edu |
 |
Heidi Manner is sophomore at The University of Kansas. She is majoring in Exercise Science with an emphasis on Pre-Med and a minor in French. She joined the Blagg laboratory as an administrative assistant in January 2008. Hsp90admin@ku.edu |
 |
Jared Mays received his Ph.D. in Pharmaceutical Sciences from the University of Wisconsin – Madison in 2007, where he worked on the development of prodrug histone deacetylase (HDAC) inhibitors under the advisership of Dr. Scott Rajski. In June 2007, he joined the Blagg laboratory as a postdoctoral researcher and is currently working on the synthesis of Hsp90 C-terminal inhibitors based on the novobiocin scaffold. Email: jmays@ku.edu |
 |
Joshua McManus received his PhD in 2007 from Murdoch University, where he worked on the synthesis of benzopyranquinones and naphthopyranquinones under the supervision of Professor Robin Giles. In October 2007 he joined the Blagg laboratory as a postdoctoral researcher and is currently preparing a combinatorial library of novobiocin analogues. jdmc@ku.edu |
 |
Justin Moyers is currently a sophomore at The University of Kansas majoring in Chemistry. In January 2008, he joined the Blagg lab and is currently working on rational drug design focused on the development for new Hsp90 inhibitors. jazzjm@ku.edu |
 |
Natalia Ortuzar received her Ph.D. from the University of London, School of Pharmacy in May 2006, where she worked on the design and synthesis of prodrug analogues of the duocarmycins under the supervision of Dr. Mark Searcey and Professor Lawrence Patterson. In July 2006 she joined the Blagg laboratory as a postdoctoral researcher and is working on the asymmetric synthesis of novel N-terminal inhibitors of Hsp90. nortuzar@ku.edu |
 |
Laura Peterson graduated in May 2007 from the University of Colorado at Colorado Springs with a B.S. in chemistry. She is currently a first-year graduate student working towards her Ph.D. working in the Blagg lab. Her current project involves the synthesis and evaluation of natural products and their analogues as Hsp90 inhibitors. lbp@ku.edu |
| Satya Upadhyayula is a junior at The University of Kansas majoring in Chemistry. She is currently working on the development of biological assays to determine the Hsp90 inhibitory activity. satyame@ku.edu | |
 |
Michael J. Urban received his B.S. in Biology and B.A. in Chemistry from Benedictine College in Atchison, KS, in 2003. After serving four years active duty as an officer in the U.S. Army, Mike joined the Medicinal Chemistry Department as a graduate student in June 2007 and the Blagg group in January 2008. His current project entails a collaborative study with Dr. Rick T. Dobrowsky (Pharmacology and Toxicology), aimed at elucidation of the mechanism that Hsp90 inhibitors exhibit for neuroprotection. mjurban@ku.edu |
